Clinical trial
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable…
NCT00003704 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003704 |
|---|---|
| Title | Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer |
| Official title | Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug, Radiation |
| Interventions | capecitabine, radiation therapy |
| Enrollment | 51 |
| Start date | Apr 1, 1999 |
| Primary completion | Jul 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Mar 15, 2004 |
| Last update posted | Jul 6, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: